Edwards Lifesciences (EW) Tops Q1 EPS by 8c; Boosts FY14 EPS Midpoint

Edwards Lifesciences (NYSE: EW) reported Q1 EPS of $1.12, $0.08 better than the analyst estimate of $1.04. Revenue for the quarter came in at $590.3 million versus the consensus estimate of $585.16 million.

Edwards Lifesciences sees FY2015 EPS of $4.10-$4.30, versus prior guidance of $4.00-$4.30 and the consensus of $4.21. Edwards Lifesciences sees FY2015 revenue of $2.3-2.5 billion, versus the consensus of $2.4 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
• Edwards Lifesciences TAVR trial shows benefit in moderate AS patients
• Truist Securities Upgrades Edwards Lifesciences (EW) to Buy